Botros, S. S., El-Lakkany, N. M., Seif el-Din, S. H., William, S., Sabra, A.-N., Hammam, O. A. and De Koning, H. P. (2020) The phosphodiesterase-4 inhibitor roflumilast impacts Schistosoma mansoni ovipositing in vitro but displays only modest antischistosomal activity in vivo. Experimental Parasitology, 208, 107793. (doi: 10.1016/j.exppara.2019.107793) (PMID:31711973)
Full text not currently available from Enlighten.
Abstract
Praziquantel (PZQ) is the sole drug used to treat schistosomiasis, and the probability of developing resistance is growing the longer it is relied upon, justifying the search for alternatives. Phosphodiesterases (PDEs), particularly the PDE4 family, have attracted considerable attention as drug targets, including in Schistosoma mansoni, and especially SmPDE4A. This study investigates the potential antischistosomal activity of human PDE4 and potent SmPDE4A inhibitor roflumilast, either alone or combined with PZQ. In vitro, roflumilast resulted in a significant, concentration-dependent reduction in egg production but not of worm viability. In vitro exposure to roflumilast in combination with a low concentration of PZQ was less effective than PZQ alone, pointing to antagonism. S. mansoni-infected mice treated with roflumilast showed significant reductions in worm burden (27%) as well as hepatic and intestinal egg burdens (~28%) two weeks post treatment. Scanning EM of worms isolated from roflumilast-treated and untreated mice did not reveal noticeable changes to their tegument. S. mansoni-infected mice treated with a fixed dosage of roflumilast and a variable dosage of PZQ resulted in a higher reduction in worm burden, reduced hepatic egg counts, absence of immature eggs and a marked increase in dead eggs, compared to PZQ alone. However, the combination resulted in increased animal mortality, probably attributable to pharmacodynamic interactions between the two drugs. Although this study marks the first report of in vivo antischistosomal potential by a PDE inhibitor, an important proof of concept, we conclude that the antischistosomal effects of roflumilast are insufficient to warrant further development.
| Item Type: | Articles |
|---|---|
| Additional Information: | This work was undertaken as part of the PDE4NPD consortium, supported by Framework Program 7 of the European Commission, grant number 602666. |
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | De Koning, Professor Harry |
| Authors: | Botros, S. S., El-Lakkany, N. M., Seif el-Din, S. H., William, S., Sabra, A.-N., Hammam, O. A., and De Koning, H. P. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Infection & Immunity |
| Journal Name: | Experimental Parasitology |
| Publisher: | Elsevier |
| ISSN: | 0014-4894 |
| ISSN (Online): | 1090-2449 |
| Published Online: | 08 November 2019 |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information